Lv61
2200 积分 2022-06-29 加入
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
6天前
已完结
Mapping the Landscape of Open Source Health Economic Models: A Systematic Database Review and Analysis: An ISPOR Special Interest Group Report
6天前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
6天前
已完结
Human immune aging
6天前
已完结
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1
6天前
已完结
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
6天前
已完结
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
7天前
已完结
Human immune aging
29天前
已完结
Revision of Pharmacological Treatment Recommendations for Cancer Pain: Clinical Guidelines from the Japanese Society of Palliative Medicine
1个月前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
1个月前
已完结
皖公网安备34019202002308
